Corporate Governance

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, post-stroke walking difficulty, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Corporate Governance Guidelines

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.

Chairperson Member Financial Expert
  Audit Committee Compensation Committee Compliance Committee Nomination
& Governance Committee
Research
& Development Committee
Barry Greene
Peder Jensen
John Kelley
Sandra Panem, Ph.D.
Lorin J. Randall
Steven M. Rauscher
Ian F. Smith
 Chairperson
 Member
 Financial Expert
AUDIT COMMITTEE
Lorin J. Randall
Steven M. Rauscher
Ian F. Smith
COMPENSATION COMMITTEE
Barry Greene
John Kelley
Sandra Panem, Ph.D.
COMPLIANCE COMMITTEE
Peder Jensen
Lorin J. Randall
Steven M. Rauscher
NOMINATIONS & GOVERNANCE COMMITTEE
Sandra Panem, Ph.D.
Lorin J. Randall
Ian F. Smith
RESEARCH & DEVELOPMENT COMMITTEE
Peder Jensen
Sandra Panem, Ph.D.
Steven M. Rauscher

Stock Quote

ACOR (Common Stock) $ 25.60 +0.19 (+0.75%) Volume: 302,788 MORE July 22, 2016

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.